Retatrutide and Loose Skin: Prevention at 28% Loss

    By Trimi Medical Team12 min read

    With retatrutide producing weight loss of 24% or more (Jastreboff et al., NEJM 2023), loose skin is a realistic concern for many patients. When the body loses a significant amount of weight rapidly, skin that was stretched over years of weight gain may not contract quickly enough to match the new body contour. Understanding the risk factors, prevention strategies, and treatment options helps patients prepare for this aspect of their transformation.

    Medical Disclaimer: This article is for informational purposes only. Retatrutide is an investigational drug not yet approved by the FDA. Consult with a board-certified plastic surgeon for evaluation of excess skin concerns.

    Risk Factors for Loose Skin

    FactorHigher RiskLower Risk
    Total weight lost100+ lbs (20%+ body weight)Under 50 lbs
    AgeOver 45Under 35
    Duration of obesity10+ yearsUnder 5 years
    Speed of weight lossMore than 2 lbs/week sustained1-2 lbs/week
    Sun damage / smokingSignificant historyMinimal
    GeneticsFamily history of poor elasticityNaturally elastic skin

    Common Areas Affected

    Loose skin from major weight loss typically affects the abdomen (most common), upper arms, inner thighs, breasts/chest, lower back/flanks, and neck and jawline. The abdomen is usually the most affected area because it experiences the greatest stretching during weight gain.

    Prevention Strategies During Retatrutide Treatment

    Build and Maintain Muscle

    Resistance training is the single most effective strategy for minimizing loose skin. Muscle fills the space that fat previously occupied, creating a firmer contour. Aim for 3-4 resistance training sessions weekly targeting all major muscle groups. Building muscle also increases basal metabolic rate, supporting continued weight loss.

    Nutrition for Skin Health

    • Protein: 1.2-1.6g per kg of ideal body weight daily to support collagen synthesis
    • Vitamin C: Essential cofactor for collagen production (citrus fruits, bell peppers, berries)
    • Zinc: Supports skin repair and elastin production
    • Omega-3 fatty acids: Support skin hydration and barrier function
    • Collagen peptides: Some evidence for improving skin elasticity (5-10g daily)
    • Adequate hydration: At least 64 oz of water daily

    Skincare

    • Daily broad-spectrum SPF 30+ sunscreen
    • Retinoid products (stimulate collagen production)
    • Body moisturizers containing hyaluronic acid
    • Avoid harsh soaps that strip natural oils

    Does Skin Tighten on Its Own?

    Yes, to a degree. Skin continues to remodel and tighten for 12-24 months after weight stabilization. Younger patients with less total weight loss and good skin elasticity may see significant improvement without intervention. Waiting at least 12-18 months after reaching goal weight before evaluating surgical options is generally recommended, as the final result may be much better than what it looks like immediately after weight loss.

    Non-Surgical Options

    • Radiofrequency treatments: Stimulate collagen contraction and remodeling
    • Ultrasound therapy (Ultherapy): Targets deeper skin layers for tightening
    • Laser treatments: Various laser modalities can improve skin tightness
    • Microneedling with radiofrequency: Combines collagen stimulation approaches

    Non-surgical options work best for mild to moderate skin laxity and are most effective in younger patients. They are not a substitute for surgery in cases of significant excess skin.

    Surgical Options

    For significant excess skin after major weight loss, surgical body contouring may be the most effective solution. Common procedures include abdominoplasty (tummy tuck), brachioplasty (arm lift), thigh lift, lower body lift, and breast lift. See our detailed guide on retatrutide and body contouring for timing and planning.

    GLP-1 Treatment With Complete Support

    Trimi offers compounded semaglutide ($99/month) and compounded tirzepatide ($125/month) with medical guidance that addresses all aspects of your weight loss journey. Learn how Trimi works.

    Frequently Asked Questions

    Will I definitely get loose skin on retatrutide?

    Not necessarily. It depends on total weight lost, age, genetics, and skin health. Patients who lose less than 50 pounds and are under 40 may see minimal loose skin. Those losing 100+ pounds are more likely to experience it.

    Does slower weight loss prevent loose skin?

    Slower weight loss gives skin more time to remodel, potentially reducing but not eliminating loose skin risk. However, with retatrutide, the rate of weight loss is largely determined by the medication and may not be easily controlled.

    Can collagen supplements help?

    Some studies suggest collagen peptide supplementation (5-10g daily) may improve skin elasticity and hydration. While not a miracle solution, it may provide modest benefit as part of a comprehensive skin health strategy.

    How long should I wait for skin to tighten before considering surgery?

    Most surgeons recommend waiting at least 12-18 months after weight stabilization. Skin continues to remodel during this period, and early surgery may yield suboptimal results if further tightening would have occurred naturally.

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    Related Reading

    What does the published clinical evidence show for retatrutide?

    Peer-reviewed evidence: Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023). Trimi is preparing for launch; compounded availability depends on FDA-cleared compounding pathways. Results vary by individual; eligibility is determined by a licensed clinician.

    Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. — Jastreboff et al. Phase 2 trial, NEJM 2023
    Retatrutide 12 mg reduced HbA1c by approximately 2.02 percentage points at 36 weeks in patients with type 2 diabetes, compared with 1.41 points on dulaglutide 1.5 mg. — Rosenstock et al. Phase 2 T2D trial, Lancet 2023
    Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. — STEP 1, NEJM 2021

    Key Takeaways

    • Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023)
    • Retatrutide 12 mg reduced HbA1c by approximately 2.02 percentage points at 36 weeks in patients with type 2 diabetes, compared with 1.41 points on dulaglutide 1.5 mg. (Source: Rosenstock et al. Phase 2 T2D trial, Lancet 2023)
    • Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. (Source: STEP 1, NEJM 2021)
    • Retatrutide is investigational and not FDA-approved as of publication. Trial findings reported here are from Phase 2 / Phase 3 studies in peer-reviewed sources cited below.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: January 7, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    Amazing company and care team support! Fast response time, no hidden fees and they actually care enough to work with you and your needs on your weight loss journey. Down 12.5 pounds in 2 months!

    Outcome: Down 12.5 lbs in 2 months

    Sarah MillerFacebook
    Arrived within 24 hours. Easy to use. Comes with everything. The year is so worth it.

    Outcome: Same-day delivery experience

    Veronica LarimoreFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2301972
    2. Rosenstock J, Frias J, Jastreboff AM, et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet.Read StudyDOI: 10.1016/S0140-6736(23)01053-X
    3. ClinicalTrials.gov (2024). A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Are Overweight (TRIUMPH-1) — NCT05929066. ClinicalTrials.gov.Read Study
    4. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2032183
    5. Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA.Read StudyDOI: 10.1001/jama.2021.3224
    6. Garvey WT, Batterham RL, Bhatta M, et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine.Read StudyDOI: 10.1038/s41591-022-02026-4

    Was this article helpful?

    Keep Reading

    Get answers to the 30 most common questions about retatrutide, from how it works and side effects to cost, availability, eligibility, and results based on Phase 2 clinical trial data.

    Retatrutide

    Retatrutide 2mg

    Retatrutide 4mg is the first therapeutic dose — where real weight loss begins. 17.5% average weight loss at this dose alone. Expected results, side effects, and when to consider escalating.

    The definitive 2026 guide to retatrutide (LY3437943): mechanism of action, Phase 2 and 3 trial results, dosing, side effects, cost, availability, eligibility, and how to get started.

    Retatrutide vs phentermine: 24.2% weight loss with a triple-agonist hormone vs 5-10% with a stimulant. Mechanism, side effects, duration, and why the comparison isn

    Start your GLP-1 journey — from $99/mo

    Get Started